

PRODUCT INFORMATION



Raltegravir (potassium salt)

Item No. 16071

CAS Registry No.: 871038-72-1

Formal Name: N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[[5-methyl-1,3,4-oxadiazol-2-yl]carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide, monopotassium salt

Synonym: MK-0518

MF: $C_{20}H_{20}FN_6O_5 \cdot K$

FW: 482.5


Purity: $\geq 98\%$

UV/Vis.: λ_{max} : 210, 312 nm

Supplied as: A crystalline solid

Storage: $-20^{\circ}C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Raltegravir (potassium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the raltegravir (potassium salt) in the solvent of choice, which should be purged with an inert gas. Raltegravir (potassium salt) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of raltegravir (potassium salt) in these solvents is approximately 2 and 1 mg/ml, respectively.

Raltegravir (potassium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, raltegravir (potassium salt) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Raltegravir (potassium salt) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Raltegravir is an orally bioavailable inhibitor of HIV-1 integrase ($IC_{50} = 15$ nM in a strand transfer assay).¹ It inhibits the spread of HIV-1IIIb infection in MT-4 cell culture with 95% cell culture inhibitory concentration (IC_{95}) values of 19 and 31 nM in medium containing 10% heat-inactivated fetal bovine serum (FBS) or 50% normal human serum, respectively. Formulations containing raltegravir have been used in combination therapy in the treatment of HIV-1 infection.

Reference

1. Summa, V., Petrocchi, A., Bonelli, F., *et al.* Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. *J. Med. Chem.* **1(18)**, 5843-5855 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM